Silence Therapeutics to Participate in September Investor Conferences
06 Setembro 2023 - 8:00AM
Business Wire
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the
“Company”), an experienced and innovative biotechnology company
committed to transforming people’s lives by silencing diseases
through precision engineered medicines, today announced that
Company management will participate in the following investor
conferences and invited investors to participate by webcast.
- Morgan Stanley Global Healthcare Conference Fireside Chat on
Monday, September 11, 2023 at 9:20am EDT
- HC Wainwright Global Investment Conference Fireside Chat on
Tuesday, September 12, 2023 at 10am EDT
- Cantor Global Healthcare Conference Formal Presentation on
Wednesday, September 27, 2023 at 4:10pm EDT
The webcasts can be accessed via the Investors section of the
Silence website at www.silence-therapeutics.com. An archived replay
of the webcasts will be available following the conference.
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence's proprietary mRNAi GOLD™ platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include zerlasiran designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address
hematological diseases. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906810931/en/
Enquiries:
Silence Therapeutics plc Gem Hopkins, Head of IR and
Corporate Communications ir@silence-therapeutics.com Tel: +1 (646)
637-3208
Silence Therapeutics (NASDAQ:SLN)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Silence Therapeutics (NASDAQ:SLN)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024